Intranasal Anti-Inflammatory Peptide Crosses Blood-Brain Barrier and Restores Function After Brain Injury
Intranasal delivery of KAFAK, a cell-penetrating anti-inflammatory peptide, crossed the blood-brain barrier in TBI mice, reduced proinflammatory cytokines, and restored neurological, memory, and motor function.
Quick Facts
What This Study Found
Intranasal KAFAK peptide traversed the BBB in TBI mice, reduced proinflammatory cytokines contributing to secondary injury, and improved or restored neurological, memory, and locomotor function after moderate traumatic brain injury.
Key Numbers
Moderate TBI model with intranasal peptide delivery showing enhanced brain uptake and reduced inflammatory markers.
How They Did This
Murine model of diffuse, moderate TBI. KAFAK administered intranasally (non-invasive). BBB penetration confirmed. Proinflammatory cytokine levels measured. Behavioral tests assessed neurological function, memory, and locomotor performance.
Why This Research Matters
TBI affects millions annually and is a leading cause of disability, yet there's no approved treatment for the secondary brain damage caused by chronic inflammation. An intranasal peptide that reduces brain inflammation and restores function could be a game-changer.
The Bigger Picture
Intranasal drug delivery is gaining traction as a way to treat brain conditions without surgery or invasive procedures. Combining this delivery route with anti-inflammatory peptides like KAFAK could open new treatment avenues for TBI, stroke, Alzheimer's, and other neuroinflammatory conditions.
What This Study Doesn't Tell Us
Mouse study — TBI models don't fully replicate human brain injury complexity. The exact dose, timing, and duration of KAFAK treatment needed for optimal benefit weren't fully defined. Long-term safety and the sustainability of functional improvements weren't assessed.
Questions This Raises
- ?What is the optimal dosing window after TBI for KAFAK to be maximally effective?
- ?Could KAFAK intranasal delivery work for chronic TBI inflammation, not just acute injury?
- ?Would this approach be effective for other neuroinflammatory conditions like stroke or neurodegenerative diseases?
Trust & Context
- Key Stat:
- Functional restoration Intranasal KAFAK peptide restored neurological, memory, and locomotor performance after moderate TBI — with no surgery or injection needed
- Evidence Grade:
- Preliminary evidence from a single animal study. Results are promising but require replication and dose-optimization before human trials.
- Study Age:
- Published in 2024; represents cutting-edge intranasal peptide delivery research for neurological conditions.
- Original Title:
- Intranasal Delivery of Cell-Penetrating Therapeutic Peptide Enhances Brain Delivery, Reduces Inflammation, and Improves Neurologic Function in Moderate Traumatic Brain Injury.
- Published In:
- Pharmaceutics, 16(6) (2024)
- Authors:
- Yanamadala, Yaswanthi, Roy, Ritika, Williams, Afrika Alake, Uppu, Navya, Kim, Audrey Yoonsun, DeCoster, Mark A, Kim, Paul, Murray, Teresa Ann
- Database ID:
- RPEP-09579
Evidence Hierarchy
Frequently Asked Questions
How does a nasal spray get drugs into the brain?
The nasal cavity is uniquely close to the brain, connected by the olfactory and trigeminal nerves. Drugs delivered intranasally can travel along these nerve pathways directly into the brain, bypassing the blood-brain barrier that blocks most drugs given by injection or pill.
Could this be used for concussions or sports-related brain injuries?
Potentially — the study used a moderate TBI model, which is similar to concussion-level injuries. If KAFAK proves effective in human trials, an intranasal spray that reduces brain inflammation after a concussion could be a breakthrough for athletes and military personnel.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09579APA
Yanamadala, Yaswanthi; Roy, Ritika; Williams, Afrika Alake; Uppu, Navya; Kim, Audrey Yoonsun; DeCoster, Mark A; Kim, Paul; Murray, Teresa Ann. (2024). Intranasal Delivery of Cell-Penetrating Therapeutic Peptide Enhances Brain Delivery, Reduces Inflammation, and Improves Neurologic Function in Moderate Traumatic Brain Injury.. Pharmaceutics, 16(6). https://doi.org/10.3390/pharmaceutics16060774
MLA
Yanamadala, Yaswanthi, et al. "Intranasal Delivery of Cell-Penetrating Therapeutic Peptide Enhances Brain Delivery, Reduces Inflammation, and Improves Neurologic Function in Moderate Traumatic Brain Injury.." Pharmaceutics, 2024. https://doi.org/10.3390/pharmaceutics16060774
RethinkPeptides
RethinkPeptides Research Database. "Intranasal Delivery of Cell-Penetrating Therapeutic Peptide ..." RPEP-09579. Retrieved from https://rethinkpeptides.com/research/yanamadala-2024-intranasal-delivery-of-cellpenetrating
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.